- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01506323
Mantram Repetition Meditation for Veterans With PTSD
August 26, 2015 updated by: US Department of Veterans Affairs
Portable Mantram Meditation for Veterans With Military Related PTSD
The aim of this study was to determine the usefulness of a portable, meditation-based intervention called the Mantram Repetition Program (MRP) for Veterans with military-related posttraumatic stress disorder (PTSD).
This study compared the individual delivery of the MRP to individual delivery of Present-Centered Therapy (PCT) at two sites in San Diego, California, and Bedford, Massachusetts.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The investigators conducted a prospective, parallel group, two-site, randomized clinical trial on the therapeutic treatment efficacy of the Mantram Repetition Program (MRP) by offering it as a stand-alone intervention, compared to an attention control condition of Present Centered Therapy (PCT) in a diverse sample of Veterans with post-traumatic stress disorder (PTSD).
Primary outcomes included clinician-assessed and self-reported PTSD symptom severity.
Secondary outcomes included insomnia, depression, anger, spiritual well-being, and mindfulness.
Veterans were were recruited from a variety of clinics, including primary care, women's health, and specialty clinics in two geographical locations within the Department of Veterans Affairs healthcare system.
Study Type
Interventional
Enrollment (Actual)
181
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92161
- VA San Diego Healthcare System
-
-
Massachusetts
-
Bedford, Massachusetts, United States, 01730
- Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years of age or older
- Read and write English fluently
- Traumatic event related to military-duty, including combat, military training accidents, and military sexual trauma
- Transportation to attend meetings and available to complete study protocols
- Stable dose and type of PTSD medications for at least 6 weeks (per chart review)
- Willing to track medication changes during study
Exclusion Criteria:
- Inability to give informed, voluntary consent
- Cognitive impairment sufficient to cause inability to complete the protocol
- Psychotic symptoms
- Dementia or other organic mental disorders that may cause inability to complete the protocol
- Significant documented alcohol/substance abuse
- Presence of severe suicidal urges or intent
- Residence in a geographical area outside of San Diego County or Bedford, Massachusetts area
Current daily practice of any skills of any meditation-based program - including, but not limited to:
- Transcendental Meditation (TM)
- Yoga
- Tai Chi
- Qi-Gong
- Vipassana or Insight Meditation
- Loving-Kindness or Compassion Meditation
- Mindfulness-Based Stress Reduction (MBSR) or other mindfulness program
- Guided Imagery
- Mantram Repetition
- Passage Meditation
- Walking Meditation
- Zen or Buddhist meditation
- Self-hypnosis, Bio-feedback, etc.
- Other participant circumstances that, in the opinion of a consensus of the study team, would interfere with the safety of prospective participants or their need for treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mantram Repetition Program (MRP)
A portable meditation-based "Mantram Repetition Program (MRP)" will be delivered individually in 8-weekly 1 hour sessions to teach a set of strategies for training attention to manage symptoms.
For this study, the program targets symptoms of posttraumatic stress disorder (PTSD) in Veterans who have experienced military-related trauma.
|
The MRP teaches three portable, mindfulness strategies to train attention and manage symptoms: 1) Mantram (sacred word) Repetition, 2) Slowing Down, and 3) One-Pointed Attention.
These tools are presented as working together synergistically and cumulatively, over time, to interrupt negative thoughts, behaviors, and emotional states such as anger, rage, irritability and impatience.
Participants choose their own words or phrases and are encouraged to practice repeating a mantram at any time or place.
In this study, MRP is delivered individually in eight weekly, 1-hour sessions, using a standardized manual, instructor guide, and homework assignments for experiential learning.
Other Names:
|
Active Comparator: Present Centered Therapy (PCT)
Present Centered Therapy (PCT) is a form of individually-delivered 8-weekly, 1 hour sessions that are problem-oriented to improve current coping.
For this study, it served as an attention control arm for the non-specific effects of individual therapist interaction.
|
The PCT is a form of individual therapy that is problem-oriented to improve current coping.
It avoids details of traumatic experiences.
In this study, it is delivered individually in 8 weekly, 1 hour sessions to serve as an active, attention control arm.
Sessions are unstructured and managed so that there is some engagement of the participant's emotional concerns with an emphasis on strengths and process encouragement rather than skills training.
Three components of PCT include 1) developing a therapeutic relationship for social support, 2) focusing on current problems and problem solving, 3) and setting goals.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinician-Administered PTSD Scale (CAPS) Diagnostic and Statistical Manual, 4th ed., Text Revision (DSM-IV)
Time Frame: Baseline to post-treatment (week 8); Baseline to 2 months post-treatment.
|
PTSD symptom severity is measured by CAPS to determine PTSD diagnosis.
The scale rates 17 items representing the Diagnostic and Statistical Manual IV (DSM-IV) criteria B (re-experiencing), C (avoidance/numbing) and D (hyper-arousal).
CAPS has demonstrated high levels of internal consistency, good inter-rater reliability, & excellent convergent validity.
The F1/I2 rule will be applied to establish the diagnosis of PTSD aligned with DSM-IV (e.g. one symptom of Criterion B, three of Criterion C, and two of Criterion D. The CAPS also includes an item to assess duration of PTSD symptoms.
CAPS total score ranges from 0-136 with higher scores indicating greater symptom severity.
|
Baseline to post-treatment (week 8); Baseline to 2 months post-treatment.
|
Re-experiencing Subscale (Criterion B) on the Clinician Administered PTSD Scale (CAPS)
Time Frame: Baseline to post-treatment (week 8); Baseline to 2 months post-treatment.
|
This subscale measures the frequency and intensity of (1) recurrent or intrusive recollections of trauma, (2) recurrent, distressing dreams of the trauma, (3) acting as if the traumatic event were recurring like a flashback, (4) intense psychological distress at exposure to internal or external cues that resemble the trauma; and/or (5) physiological reactivity on exposure to internal or external cues that symbolize or resemble an aspect of the trauma.
Duration of these symptoms is greater than one month and symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of of functioning.
Scores can range from 0 to 40 and higher scores mean greater severity of re-experiencing.
|
Baseline to post-treatment (week 8); Baseline to 2 months post-treatment.
|
Avoidance Subscale (Criterion C) on the Clinician Administered PTSD Scale (CAPS)
Time Frame: Baseline to post-treatment (week 8); Baseline to 2 months post-treatment.
|
This subscale measures the frequency and intensity of persistent avoidance of stimuli associated with the trauma and numbing of general responsiveness as indicated by 3 or more of the following: (1) efforts to avoid thoughts, feelings, or conversations associated with the trauma, (2) efforts to avoid activities, places or people that arouse recollections of the trauma, (3) inability to recall an important aspect of the trauma, (4) markedly diminished interest or participation in significant activities, (5) feelings of detachment or estrangement from others, (6) restricted range of affect, and/or (7) sense of a foreshortened future.
Duration of these symptoms is greater than one month and causes clinically significant distress or impairment in social, occupational, or other important areas of of functioning.
Scores range from 0 to 56 with higher scores indicating greater severity of avoidance.
|
Baseline to post-treatment (week 8); Baseline to 2 months post-treatment.
|
Hyperarousal (Criterion D) on the Clinician Administered PTSD Scale (CAPS)
Time Frame: Baseline to post-treatment (week 8); baseline to 2 months post-treatment.
|
This subscale measures the frequency and intensity of increased arousal as indicated by two or more of the following: (1) difficulty falling or staying asleep, (2) irritability or outbursts of anger, (3) difficulty concentrating, (4) hypervigilance, and/or (5) exaggerated startle response.
Duration of these symptoms is greater than one month and causes clinically significant distress or impairment in social, occupational, or other important areas of of functioning.
Scores range from 0 to 40.
Higher scores indicate greater severity of symptoms.
|
Baseline to post-treatment (week 8); baseline to 2 months post-treatment.
|
PTSD Checklist-Military Version [Diagnostic and Statistical Manual (DSM) IV-TR Version]
Time Frame: Baseline to post-treatment (week 8); Baseline to 2-months post-treatment.
|
PCL-M: PTSD Checklist-Military version (PCL-M) is a 17-item self-report screening instrument for PTSD symptoms related to military trauma.
Items are scored on a 1 (not at all bothersome) to 5 (extremely bothersome) Likert scale.
Total scores range from 17 to 85. Higher scores indicate greater symptom bothersomeness.
A score of > 50 can suggest PTSD Test-retest reliability is high (r = 0.96) and validity is adequate, with a Kappa of 0.64 agreement for PTSD diagnosis compared to the Structured Clinical Interview for DSM-IV.
|
Baseline to post-treatment (week 8); Baseline to 2-months post-treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insomnia Severity Index (ISI)
Time Frame: Baseline to post-treatment (week 8); baseline to 2 months post-treatment.
|
ISI is a widely used measure of insomnia with well-established reliability and validity.
It consists of seven items, three of which assess severity of insomnia (i.e., degree of difficulty falling asleep, staying asleep, and waking too early).
The remaining questions tap satisfaction with sleep pattern, effect of sleep on daytime and social functioning, and concern about current sleep difficulties.
Both categorical and continuous measures of sleep difficulties can be assessed.
Items are rated on a 0-4 Likert scale with higher scores meaning greater insomnia.
Total scores range from 0-28.
Original results were interpreted as 0-7 = no clinically significant insomnia, 8-14 = sub-threshold insomnia, 15-21 = moderately severe clinical insomnia and 21-28 = severe clinical insomnia.
Later recommendations for a clinical, not community sample, are a cut-off of 11 points.
|
Baseline to post-treatment (week 8); baseline to 2 months post-treatment.
|
Patient Health Questionnaire (PHQ-9) for Depression
Time Frame: Baseline to post-treatment (week 8); Baseline to 2-months post-treatment.
|
PHQ-9 is a 9-item depression screening tool based on the diagnostic criteria for major depressive disorder in the DSM-IV.
Each item is rated from a 0 (not at all) to 3 (nearly every day) scale.
Items are summed and total scores range from 0 to 27.
Higher scores indicate worse depression.
A score of 11 or more considered probable depression and 20 or more is considered severe depression.
It is well-validated and widely-used in medical settings such as primary care.
The PHQ-9 includes the two major symptom domains characteristic of depression: affective and somatic symptoms.
|
Baseline to post-treatment (week 8); Baseline to 2-months post-treatment.
|
Spielberger State Anger Inventory-Short Form
Time Frame: Baseline to post-treatment (week 8); baseline to 2-months post-treatment.
|
Spielberger State Anger Inventory-Short Form is a 10-item questionnaire with 4-point Likert scale to measure anger as an emotional state.
Scores range from 10 to 40 with higher scores indicating more anger.
Concurrent validity has been supported by correlations with measures of hostility, neuroticism, and anxiety.
Internal consistency reliability has been reported as good to excellent.
|
Baseline to post-treatment (week 8); baseline to 2-months post-treatment.
|
Spielberger Trait Anger Inventory-Short Form
Time Frame: Baseline to post-treatment (week 8); baseline to 2-months post-treatment.
|
Spielberger Trait Anger Inventory-Short Form is a 10-item questionnaire with 4-point Likert scale used to measure anger as a personality trait.
Scores range from 10 to 40 with higher scores indicating more trait anger.
Concurrent validity has been supported by correlations with measures of hostility, neuroticism, and anxiety.
Internal consistency reliability has been reported as good to excellent.
|
Baseline to post-treatment (week 8); baseline to 2-months post-treatment.
|
Functional Assessment of Chronic Illness Therapy-Spiritual Wellbeing Scale-Expanded (FACIT-SpEx)
Time Frame: Baseline to post-treatment (week 8); baseline to 2-months post-treatment.
|
The FACIT-SpEx was developed to assess spiritual components (e.g., harmony, meaning, purpose in life, peacefulness, faith/assurance) of quality of life using 23 items rated on a 5-point Likert scale from 0 (not at all) to 4 (very much).
Total scores range from 0 to 92.
Higher scores indicating greater spiritual well-being.
Validity has been demonstrated by significant Pearson correlations between measures of quality of life, mood, and religious growth.
It has demonstrated internal consistency reliability.
|
Baseline to post-treatment (week 8); baseline to 2-months post-treatment.
|
Five Facet Mindfulness Questionnaire (FFMQ)
Time Frame: Baseline to post-treatment (week 8); baseline to 2-months follow-up.
|
FFMQ a 39-item scale that measures five components of mindfulness: observing; describing; acting with awareness; non-judging of inner experience; and non-reactivity to inner experience.
Each subscale contains either 7 or 8 items that are rated on a 1 (never or very rarely true) to 5 (very often or always true) Likert scale.
Items are randomly reversed scored and higher scores represent greater levels of mindfulness.
Total scores range from 39 to 195.
|
Baseline to post-treatment (week 8); baseline to 2-months follow-up.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jill E. Bormann, PhD RN, San Diego Veterans Healthcare System
- Principal Investigator: A. Rani Elwy, PhD MSc BA, Edith Nourse Rogers Memorial Veterans Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Bormann JE, Plumb DN, Beck DJ, Glickman M, Zhao S, Osei-Bonsu PE, Johnston JM, Herz L, Elwy AR. Portable meditation-based mantram program reduces PTSD symptoms in veterans: A randomized controlled trial. Poster session presented at: International Society for Traumatic Stress Studies Annual Symposium; 2014 Nov 1; Miami, FL.
- Malaktaris A, McLean CL, Mallavarapu S, Herbert MS, Kelsven S, Bormann JE, Lang AJ. Higher frequency of mantram repetition practice is associated with enhanced clinical benefits among United States Veterans with posttraumatic stress disorder. Eur J Psychotraumatol. 2022 Jun 10;13(1):2078564. doi: 10.1080/20008198.2022.2078564. eCollection 2022.
- Bormann JE, Thorp SR, Smith E, Glickman M, Beck D, Plumb D, Zhao S, Ackland PE, Rodgers CS, Heppner P, Herz LR, Elwy AR. Individual Treatment of Posttraumatic Stress Disorder Using Mantram Repetition: A Randomized Clinical Trial. Am J Psychiatry. 2018 Oct 1;175(10):979-988. doi: 10.1176/appi.ajp.2018.17060611. Epub 2018 Jun 20.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2012
Primary Completion (Actual)
March 1, 2014
Study Completion (Actual)
June 1, 2015
Study Registration Dates
First Submitted
December 19, 2011
First Submitted That Met QC Criteria
January 9, 2012
First Posted (Estimate)
January 10, 2012
Study Record Updates
Last Update Posted (Estimate)
September 2, 2015
Last Update Submitted That Met QC Criteria
August 26, 2015
Last Verified
August 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SPLE-003-11S
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stress Disorders, Post-Traumatic
-
University of California, Los AngelesDefense Advanced Research Projects Agency; Defense Group, Inc.CompletedPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder, ChronicUnited States
-
Weill Medical College of Cornell UniversityCompletedPost-traumatic Stress Disorder | Complex Post-Traumatic Stress DisorderUnited States
-
Oregon Health and Science UniversityNational Center for Complementary and Integrative Health (NCCIH); Oregon Clinical...CompletedPost-Traumatic Stress DisordersUnited States
-
US Department of Veterans AffairsEmory UniversityWithdrawnPost-Traumatic Stress Disorders
-
University of KonstanzGerman Research Foundation; NGO vivo e.V.; GTZ-German Technical Cooperation,... and other collaboratorsCompletedPost-Traumatic Stress DisordersSri Lanka
-
University Hospital, ToulouseCompletedPost-traumatic StressFrance
-
University Hospital, LilleNot yet recruiting
-
Steinn SteingrimssonRecruiting
-
Direction Centrale du Service de Santé des ArméesRecruitingPost-traumatic Stress DisorderFrance
-
VA Greater Los Angeles Healthcare SystemUniversity of California, Los AngelesRecruitingPost-Traumatic Stress DisorderUnited States
Clinical Trials on Mantram Repetition Program (MRP)
-
US Department of Veterans AffairsCompleted
-
VA Office of Research and DevelopmentCompleted
-
National Center for Complementary and Integrative...University of California, San DiegoCompleted
-
Centre for Addiction and Mental HealthCompletedPost Traumatic Stress Disorder | Substance Use DisordersCanada
-
VA Office of Research and DevelopmentCompletedChronic Low Back Pain | Chronic Neck Pain | Post-Traumatic Stress DisorderUnited States
-
Superior UniversityNot yet recruiting
-
Maastricht University Medical CenterFonds NutsOhra; Adelante, Centre of Expertise in Rehabilitation and Audiology; Stichting VooruitCompleted